Pascal Millet
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Pascal Millet has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Fawaz Fawaz
Univ. Bordeaux, Laboratory of Galenic Pharmacy and Biopharmacy, Bordeaux, France
2 shared publications - Piero Olliaro
ISARIC, Pandemic Sciences Institute, Nuffield Department of Medicine, University of Oxford , Oxford
2 shared publications - Tina Kauss
Inserm, U1212, UMR CNRS CNRS 5320, Université de Bordeaux, F-33076, Bordeaux, France
2 shared publications - Alexandra Gaubert
Université de Lyon, Institut des Sciences Analytiques UMR 5280 CNRS, Université Claude Bernard Lyon 1, ENS Lyon, 5 rue de la Doua, 69100, Villeurbanne, France.
1 shared publication Anne-Marie Lagueny
1 shared publicationAntonella Caminiti
1 shared publication
Latest Publications
- Open Access
- 1 January 2013
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 441 (1-2) , 218-226
Pharmaceutical development and optimization of azithromycin suppository for paediatric use
- 1 January 2013
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 441 (1-2) , 218-226
Open AccessPharmaceutical development and optimization of azithromycin suppository for paediatric use
- 16 August 2010
- Vol. 395, 198-204
Fixed artesunate-amodiaquine combined pre-formulation study for the treatment of malaria.
Artemisinin-based combination therapies, including artesunate (AS) + amodiaquine (AQ), are the currently recommended first-line treatment of uncomplicated falciparum malaria. Fixed-dose co-formulations offer logistic and adherence advantages. This paper reports the initial research phase of the pre-development process of an AS-AQ formulation, further developed by the Drug for Neglected Diseases Initiative (DNDi). Results demonstrate that AS and AQ are not compatible, and AS degradation is related to three main parameters: water content (>1%), elevated temperature (80 degrees C in dry condition) and possibly the 4-aminoquinoline moiety. Furthermore, AS and AQ incompatibility led to AS degradation and pharmaco-technical changes in classical wet granulation tablets. Both active principles are stable as dry powders. These investigations led to further development of various co-formulations, including the bilayer tablet currently on the market.
- 16 August 2010
- Vol. 395, 198-204
Fixed artesunate-amodiaquine combined pre-formulation study for the treatment of malaria.
Artemisinin-based combination therapies, including artesunate (AS) + amodiaquine (AQ), are the currently recommended first-line treatment of uncomplicated falciparum malaria. Fixed-dose co-formulations offer logistic and adherence advantages. This paper reports the initial research phase of the pre-development process of an AS-AQ formulation, further developed by the Drug for Neglected Diseases Initiative (DNDi). Results demonstrate that AS and AQ are not compatible, and AS degradation is related to three main parameters: water content (>1%), elevated temperature (80 degrees C in dry condition) and possibly the 4-aminoquinoline moiety. Furthermore, AS and AQ incompatibility led to AS degradation and pharmaco-technical changes in classical wet granulation tablets. Both active principles are stable as dry powders. These investigations led to further development of various co-formulations, including the bilayer tablet currently on the market.